- AVF Academy
- Superficial Venous Science: Obesity, Ablation and Ulcers
Superficial Venous Science: Obesity, Ablation and Ulcers
Seven Abstracts on Superficial Venous Disease
The opening scientific session paired registry analyses with randomized data and a consensus exercise.
Who Heals and Who Does Not
- Social vulnerability: across 534 patients treated for new venous leg ulcers, higher vulnerability meant longer standing ulcers, more debridement and antibiotics, slower healing at 24 weeks and more recurrence.
- Obesity: in roughly 10,000 registry ablation patients, absolute improvement in severity and symptom scores was flat across body mass index, so delaying surgery for weight loss is hard to justify. A separate study found higher great saphenous vein pressure at higher body mass index.
- Peri ulcer foam: the randomized trial reported shorter healing time and, over follow up averaging 2.2 years, less recurrence and longer ulcer free time.
Comparing and Classifying
A registry comparison found more paresthesia after thermal ablation and more hematoma and pigmentation after nonthermal treatment, with discussants warning that significance in very large datasets is not the same as clinical relevance. A Delphi panel proposed device specific language for thrombus extension after ablation, which prompted sharp debate over whether routine scanning afterwards is warranted at all.
Related
Mar 1, 2026
Seven papers, covering antithrombotic therapy after iliac vein stenting, frailty and exercise in venous leg ulcer healing, GL... more details Jul 26, 2024
This issue reviews evidence on medical and procedural treatment of chronic venous disease. It summarizes AVF guideline recomm... more details May 29, 2024
This Vein Specialist newsletter issue examines new compression research from VENOUS2024. A Stony Brook study found that Unna'... more details Oct 10, 2023
This SVS webinar translated the 2022 multisociety varicose vein guidelines into practice across six talks. Presenters covered... more details Feb 17, 2025
A hands-on sclerotherapy workshop reviews the FDA-approved sclerosing agents polidocanol and sodium tetradecyl sulfate, their... more details Jan 18, 2025
This joint AVF and EVLA phlebology webinar reviewed three JVS Venous and Lymphatic papers plus an industry update. A German r... more details Mar 5, 2024
This session opened with a masterclass on ethanol sclerotherapy for venous and lymphatic malformations, showing durable ablat... more details Mar 3, 2024
This AVLS showcase presents society position statements and registry findings on venous ablation. Cyanoacrylate closure guida... more details Feb 23, 2023
This research update session reviewed AVF-supported projects advancing venous care. One talk described refinement of the Capr... more details Jan 22, 2022
This BD sponsored AVF superficial venous summit covered thermal versus non-thermal ablation efficacy and cost data, favoring... more details Dec 23, 2021
The fourth, revised and expanded edition of the Handbook of Venous Disorders is a 744-page reference covering evaluation, dia... more details Mar 20, 2021
This scientific session opened with a 1683 patient survey finding 56.6 percent report worsened lower extremity edema in summe... more details 
